

Navitas titled as a Leader in IDC MarketScape

13 July 2018 | News

Navitas Life Sciences is strongly differentiated from its more traditional market competitors by its broad portfolio of clients, ranging from small and midsize organizations to large global pharmaceutical companies



A TAKE Solutions Enterprise

TAKE Solutions announced that its dedicated life sciences company, Navitas has been recognized as a 'Leader' in the IDC MarketScape: Worldwide Life Science R&D BPO Services 2018 Vendor Assessment.

Leadership in this study is based on the breadth of life science R&D business process outsourcing services offered, geographical footprint and global delivery capabilities, industry-specific expertise, and diligent vetting of customer references to examine vendor capabilities.

Navitas Life Sciences was one of nine life science R&D IT BPO vendors selected to participate in this study based on the IDC MarketScape's stringent research and due diligence process.

IDC MarketScape's vendor assessment:

"Navitas Life Sciences has extensive experience working with pharmaceutical and biotechnology companies of all sizes and across multiple geographies. Navitas Life Sciences is strongly differentiated from its more traditional market competitors through its broad portfolio of clients, ranging from small and midsize organizations to large global pharmaceutical companies. Deep, task-level client experience over a wide variety of specific BPO services also separates Navitas Life Sciences from its

peers in this IDC MarketScape. Relative to other vendors discussed in this study and based on feedback from multiple customer references, Navitas Life Sciences received high marks for its technical skills and capabilities, a deep bench and proactive approach to project work, and ability to contribute as a strategic partner when needed."

Ram Yeleswarapu, President, Navitas Life Sciences said, "We are honored that our domain centricity in Life Sciences was recognized in the form of a listing as 'Leader' in the prestigious IDC MarketScape 2018 Assessment". Speaking on the latest technological innovations, he also added," Artificial Intelligence (AI) will significantly transform or impact the life sciences space. This along with robotics and cognitive technologies is important for better outcomes, safety, and compliance and lower costs. The use of AI will provide anticipated savings of nearly US\$ 150 billion by the mid-2020s for the United States' healthcare economy."

Alan Louie, Research Director of IDC Health Insights' Life Science R&D Strategy and Technology research, noted, "While still somewhat smaller than its traditional IT outsourcing counterpart, BPO in the life sciences remains an important contributor to industry success. The scope of life science R&D BPO continues to expand as more and more processes are operationalized and preferred IT partners are tasked with implementing and maintaining new processes and procedures. As a result, leading IT service providers are increasingly working as partners with their industry sponsors to deliver operational excellence while contributing to ongoing industry transformation that will ultimately automate well-defined, highly repetitive tasks. While IDC continues to expect that IT outsourcing overall will continue to grow by double digits over the next 5–10 years, we also believe that BPO spending has stabilized and should remain relatively constant over the near term."